Figure 7
Establishment of m6A signatures. (A) Dynamic changes in the m6A-related patterns, ACRG molecular subtypes, and m6A-related scores are illustrated by an alluvial diagram. (B) The relationship between m6A-related scores and the known gene signatures in the ACRG cohort by Spearman analysis. Blue represents the negative correlation, and red represents the positive correlation. (C) Distinction in innate immune-activated pathways and stromal-activated pathways between m6A-related scores. Statistical differences were tested by one-way ANOVA between m6A-related scores. The statistical P-value was represented by the asterisks (*P < 0.05; **P < 0.01; ***P < 0.001). (D) Differences in m6A-related scores among three different m6A-related patterns and among four ACRG molecular subtypes. (E) Survival analysis for high (71 cases) and low (217 cases) m6A-related score groups in the ACRG cohort by Kaplan–Meier curves (HR, 1.63 [1.10–2.44]); P < 0.0001, Log-rank text). (F) Survival analysis was used for patent groups classified into four groups based on m6A-related scores and treatment with adjuvant chemotherapy using Kaplan–Meier curves. H, high; L, low; ADJC, adjuvant chemotherapy (P < 0.0001, Log-rank test).
